3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Enrolling by invitation
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Gastrointestinal
1
CNS
1
Breast
1
Conditions
Brain Neoplasms
276
Glioblastoma
250
Glioma
156
Astrocytoma
99
Central Nervous System Neoplasms
70
Gliosarcoma
69
Oligodendroglioma
63
Neuroblastoma
63
Neoplasms
52
Breast Neoplasms
44
Melanoma
42
Carcinoma, Non-Small-Cell Lung
38
Neoplasm Metastasis
33
Medulloblastoma
30
Lymphoma
29
Recurrence
28
Lung Neoplasms
27
Ependymoma
24
Sarcoma
20
Ovarian Neoplasms
19
Lymphoma, Follicular
19
Precursor Cell Lymphoblastic Leukemia-Lymphoma
18
Meningioma
18
Lymphoma, Non-Hodgkin
18
Leukemia
18
Meningeal Carcinomatosis
17
Burkitt Lymphoma
17
Multiple Myeloma
16
Lymphoma, Large B-Cell, Diffuse
16
Diffuse Intrinsic Pontine Glioma
15
Interventions
brolucizumab
1
aflibercept
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Macular Degeneration
×
CNS
×
Clear all
NCT03710564
2023-01-30
MERLIN
Novartis
Phase 3
Terminated
535 enrolled
14 charts